In 2011, the two companies planned to work together in more than 50 countries, but recently they announced they would scale back their agreement to 17 countries including the U.S.
The agreement still covers more than 90 percent of the anticipated diabetes drug market, they said in a press release. In the countries no longer covered under the alliance, both Eli Lilly and Boehringer Ingelheim will market individual products.
The companies have launched three new diabetes treatments under the alliance, with a fourth one earning tentative approval in the U.S.
A spokesman for Eli Lilly said that diabetes drug sales are expected to slow next year due to new pricing pressure in the U.S., surprising analysts who had predicted significant growth in that sector due to increased caseloads and a more competitive drug market.